Annual report
7133.TEDINET S100W4IH
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 23 passed
Key figures · 122
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥711m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥717m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥970m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥655m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥719m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥441m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥719m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥441m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥7.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.4bn | at 2024-03-31 | Cons. | Assets |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.5bn | at 2023-03-31d | Cons. | Net assets |
| Cash and deposits | ¥566m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥688m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥566m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥688m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥568m | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥771m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥707m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥474m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥419m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥539m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥101.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.92 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.26 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥332.65 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥231.46 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 35.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 26.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 708 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 544 | at 2024-03-31 | Cons. | Number of employees |
| Revenue | ¥10.0bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥8.3bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥6.7bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥707m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥719m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥558m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥506m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥251m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥988m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥655m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥730m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥441m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥383m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥328m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥97m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥4.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.9bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.5bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.8bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥2.8bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.1bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥609m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥512m | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥661m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥568m | at 2023-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥720m | at 2022-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥538m | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥342m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥485m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥352m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥383m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥320m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥111m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥17m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥37m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥102.61 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.06 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.92 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.9 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.99 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥99.37 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.28 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥50.82 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥43.32 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥334.15 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥231.48 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥207.61 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥153.22 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥178.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 45.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.4% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 36.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 28.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.0% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 7,277,200 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 7,246,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,572,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,499,100 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,369 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 708 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 544 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 442 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 329 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 312 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥21m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 1 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥74m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | −¥14m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥18m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥9m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥612m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥548m |
| Home Visit Pharmacist Servicereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥388m |
| Home Visit Pharmacist Servicereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥102m |
| Home Visit Pharmacist Servicereportable segment | employees | at 2025-03-31 | 378 pure |
| Home Visit Pharmacist Servicereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥7.1bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥7.1bn |
| Home Visit Pharmacist Servicereportable segment | segment assets | at 2025-03-31 | ¥2.1bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥647m |
| Kirari Primereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥16m |
| Kirari Primereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥27m |
| Kirari Primereportable segment | employees | at 2025-03-31 | 56 pure |
| Kirari Primereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Kirari Primereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Kirari Primereportable segment | segment assets | at 2025-03-31 | ¥545m |
| Kirari Primereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥783m |
| Primary Care Homereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥183m |
| Primary Care Homereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥132m |
| Primary Care Homereportable segment | employees | at 2025-03-31 | 229 pure |
| Primary Care Homereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Primary Care Homereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Primary Care Homereportable segment | segment assets | at 2025-03-31 | ¥3.8bn |
| Primary Care Homereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥184m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥587m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥261m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| —segment total | segment assets | at 2025-03-31 | ¥6.4bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥608m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥267m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥6m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥35m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥35m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥61m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥9m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥8m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥8m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥854m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥409m |
| Home Visit Pharmacist Servicereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥317m |
| Home Visit Pharmacist Servicereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥84m |
| Home Visit Pharmacist Servicereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.5bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.5bn |
| Home Visit Pharmacist Servicereportable segment | segment assets | at 2024-03-31 | ¥2.0bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥635m |
| Kirari Primereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥116m |
| Kirari Primereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥26m |
| Kirari Primereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥837m |
| Kirari Primereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥837m |
| Kirari Primereportable segment | segment assets | at 2024-03-31 | ¥238m |
| Kirari Primereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥485m |
| Primary Care Homereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥113m |
| Primary Care Homereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥50m |
| Primary Care Homereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥883m |
| Primary Care Homereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥883m |
| Primary Care Homereportable segment | segment assets | at 2024-03-31 | ¥3.2bn |
| Primary Care Homereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥8m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥546m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥160m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| —segment total | segment assets | at 2024-03-31 | ¥5.4bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥552m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥166m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 1 pure |
| Home Visit Pharmacist Servicereportable segment | employees | at 2025-03-31 | 378 pure |
| Kirari Primereportable segment | employees | at 2025-03-31 | 56 pure |
| Primary Care Homereportable segment | employees | at 2025-03-31 | 229 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,409
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 708 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 137 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 37.8 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 2.6 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 4523000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E37198-000HomeVisitPharmacistServiceReportableSegmentMember | 378 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E37198-000HomeVisitPharmacistServiceReportableSegmentMember | 91 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E37198-000KirariPrimeReportableSegmentMember | 56 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E37198-000KirariPrimeReportableSegmentMember | 0 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E37198-000PrimaryCareHomeReportableSegmentMember | 229 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E37198-000PrimaryCareHomeReportableSegmentMember | 43 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 0 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 44 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 3 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 708 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 137 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.136 | |
| All employees calculated based on provisions of article714 item1 of ordinance for enforcement of act on childcare leave caregiver leave and other measures for the welfare of workers caring for children or other family members ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.846 | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.663 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.697 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.770 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 75.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 64.5 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 3 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 2 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 80 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 164 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 80 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 94.1 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 10 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 3 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 625000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E37198-000HomeVisitPharmacistServiceReportableSegmentMember | 387000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E37198-000KirariPrimeReportableSegmentMember | 15000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E37198-000PrimaryCareHomeReportableSegmentMember | 182000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OtherReportableSegmentsMember | 20000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 17000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 7277200 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 7277200 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 7277200 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 7277200 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 5 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 13 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 19 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 2 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 657 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 23 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |